Clinical trials
Locally Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting locally advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 3,522 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05926700RecruitingPhase 2
Testing cadonilimab plus anlotinib for advanced soft tissue sarcoma
This Phase 2 study tests two medicines (cadonilimab and anlotinib) in people with advanced soft tissue sarcoma whose cancer grew after standard first treatment. It aims to see whether the combination can shrink tumors and improve safety.
HangzhouAges 18 years+ - NCT05923684Recruiting
English prostate cancer visit feedback tool for shared decisions
This trial tests an English computer tool that gives feedback during prostate cancer treatment visits. It aims to help you and your clinician make more informed, shared decisions about next treatment steps.
Los Angeles, CaliforniaAges 18 years+ - NCT05865002RecruitingPhase 1
Safety and drug test for AUR107 in advanced cancers
This early-phase study tests whether AUR107 is safe and may help shrink or control advanced solid tumors that have come back or progressed. You may be considered if standard treatments no longer work and you meet specific blood, organ, and health requirements.
Vijayawada, Andhra PradeshAges 18 years+ - NCT05874414RecruitingPhase 1/Phase 2
Combination therapy for advanced KRAS-mutated bile duct cancer
This trial tests a new combination of two drugs, GNS561 and trametinib, for people with advanced bile duct cancer (cholangiocarcinoma) that has a specific genetic change called a KRAS mutation. The goal is to see if this combination can shrink tumors or slow the disease after prior chemotherapy.
Los Angeles, CaliforniaAges 18 years+ - NCT05851924RecruitingPhase 2
Nalirifox plus radiation for nonmetastatic pancreatic cancer
This trial studies Nalirifox (chemotherapy) given together with radiation therapy for pancreatic ductal adenocarcinoma that has not spread to distant organs. It may help shrink the cancer and improve local control, especially when surgery is not an option right now.
Basking Ridge, New JerseyAges 18 years+ - NCT05723107RecruitingPhase 1
Testing an endoscopic treatment for pancreatic cancer that can't be removed
This early-phase trial is testing a new endoscopic (from inside the stomach) approach for pancreatic ductal adenocarcinoma that is locally advanced and cannot be removed with surgery. It may help some people who have already tried first chemotherapy and still have a tumor confined to the pancreas area (no spread).
New York, New YorkAges 18 years+ - NCT05796102Recruiting
Testing an MRI-PET scan for esophagus cancer planning
This study tests whether a combined PET-MRI scan can be done safely and used to help plan treatment for people with locally advanced esophageal cancer. It may improve how doctors map the cancer and plan radiation therapy, but it is mainly a feasibility (testing-setup) study.
Toronto, OntarioAges 18 years+ - NCT05785741RecruitingPhase 1/Phase 2
DB-1310 for advanced solid tumors after standard treatment fails
This early-phase study tests DB-1310 in people with advanced or metastatic solid cancers that have come back or worsened after standard treatments. It aims to find the safest dose and whether it can help shrink tumors or slow cancer growth.
Sacramento, CaliforniaAges 18 years+ - NCT05749588RecruitingPhase 2
Study for advanced triple-negative breast cancer after prior treatments
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
ShanghaiAges 18 years+ - NCT05719558RecruitingPhase 1
Study of ASP1002 for adults with solid tumors
This trial tests a new drug called ASP1002, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to see if ASP1002 can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT05739591Recruiting
Long-term follow-up for people treated in a breast cancer trial
This study checks how well a previous early breast cancer treatment works over the long term and monitors safety. It may help you and future patients by providing long-term results from the original trial.
Innsbruck, TriolAges 18 years+ - NCT05722886RecruitingPhase 2/Phase 3
Screening trial for rare cancer gene changes in existing medicines
This trial checks whether existing cancer medicines can help people whose tumors have specific “gene changes” (mutations). You may be assigned to a treatment arm that matches your tumor’s gene results after fresh biopsy and blood testing.
BelfastAges Any age - NCT05526989RecruitingPhase 2
Dostarlimab plus niraparib for advanced penile cancer
This Phase 2 study tests whether combining dostarlimab (an immunotherapy) with niraparib (a cancer pill) can shrink advanced penile cancer and keep it from growing. It may help people whose cancer has progressed after limited prior treatments, and who have not had certain immune therapies before.
Tampa, FloridaAges 18 years+ - NCT04925609RecruitingPhase 1/Phase 2
Brigatinib for young people with ALK-positive cancer
This trial tests brigatinib, a targeted pill medicine, in children and young adults with ALK-positive cancers (including ALCL and IMT, plus some other solid tumors). It’s designed to see how well it works and what side effects it causes in people whose tumors have a specific ALK change.
ParisAges 1–25 - NCT04430452RecruitingPhase 2
Durvalumab with or without tremelimumab after liver radiation
This study tests whether the immunotherapy drugs durvalumab (with or without tremelimumab) can help control hepatocellular carcinoma (liver cancer) after you receive palliative, targeted radiation. It especially focuses on people whose cancer continued to grow after, or without, certain prior immune therapies.
San Francisco, CaliforniaAges 18 years+ - NCT05614739RecruitingPhase 1
Study of vepugratinib for cancers with FGFR3 gene changes
This study tests a new pill, vepugratinib, for people whose cancer has a specific change in a gene called FGFR3. The drug targets this gene change to try to slow or shrink the cancer, and may be an option if standard treatments have not worked.
Tucson, ArizonaAges 18 years+ - NCT05584670RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This is an early (Phase 1/2) study of SAR445877, a new drug, in adults with advanced or metastatic solid cancers. It aims to find the safest dose and learn whether it can shrink tumors or help control disease when standard treatments aren’t available or no longer work.
Newark, DelawareAges 18 years+ - NCT05570422RecruitingPhase 1
Safety and early benefits of an injection plus radiation for cervical cancer
This Phase 1 study tests whether KRC-01, given by injection into the tumor, is safe and tolerable when combined with standard chemoradiation for locally advanced cervical cancer. It also looks for early signs that the treatment can shrink tumors.
ChandigarhAges 18 years+ - NCT05539196Recruiting
Registry for Exablate treatment in Parkinson’s with medication problems
This trial is a real-world registry that follows people with Parkinson’s who are planning to get an Exablate 4000 procedure (a focused ultrasound treatment) for one-sided symptoms that are difficult to control with medication. It mainly checks outcomes and safety over time, helping doctors understand how well this treatment works in everyday care.
Baltimore, MarylandAges 30–99 - NCT05528952RecruitingPhase 2
Vaccine plus immunotherapy for unresectable liver cancer
This Phase 2 trial studies whether adding a cancer vaccine (to help the immune system recognize your tumor) to two medicines—atezolizumab and bevacizumab—can better control unresectable or advanced liver cancer. It’s for people who haven’t had prior whole-body (systemic) cancer treatment.
BesançonAges 18 years+ - NCT05443126RecruitingPhase 1/Phase 2
Testing a new RET drug for advanced lung cancer
This Phase 1/2 study tests lunbotinib, a new medicine that targets a specific lung-cancer change called RET. It aims to see how well it works and how safe it is for adults with advanced RET-altered non-small cell lung cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT05423262RecruitingPhase 1/Phase 2
TRK-950 for advanced solid tumors that standard treatment can’t control
This trial tests TRK-950 in people with advanced (locally advanced or metastatic) solid tumors when standard treatments have stopped working or aren’t available. It may help by trying a new treatment approach when current options are limited.
Nagoya, Aichi-kenAges 18 years+ - NCT05317819RecruitingPhase 3
Test ADI-PEG 20 versus placebo for advanced liver cancer
This study tests whether ADI-PEG 20 helps people with advanced, unresectable hepatocellular carcinoma (liver cancer) who have high arginine levels. Participants get ADI-PEG 20 or a placebo to see which works better and improves outcomes.
ChanghuaAges 18–99 - NCT05382559RecruitingPhase 1
Study drug for advanced cancers with KRAS G12D mutation
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
Duarte, CaliforniaAges 18 years+
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 3,522 recruiting locally advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.